GlassScriptPhysician profile
Erica Still
NPI 1699332510
$2,937.85
in general payments reported to CMS, 2019-2025
22 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.33 · 2022: $24.69 · 2023: $724 · 2024: $755 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,538 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.56 |
| Education | $294.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.27 | 2023-2025 | |
| Janssen Biotech, INC. | $314.69 | 2023-2025 | Tremfya |
| Genzyme Corporation | $268.78 | 2023-2025 | |
| Pfizer INC. | $202.89 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $190.16 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $177.93 | 2023-2025 | Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $156.89 | 2021-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $144.94 | 2023-2025 | Sotyktu |
| Ucb, INC. | $122.15 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $120.00 | 2024-2025 | Nemluvio, Aklief |
| Incyte Corporation | $115.39 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $87.97 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Amgen INC. | $61.16 | 2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $56.81 | 2021-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48.96 | 2024 | Olumiant, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.73 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Mayne Pharma Commercial LLC | $26.28 | 2025 | |
| Leo Pharma INC. | $24.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.97 | 2023 | Spevigo |
| Organon LLC | $3.24 | 2025 | |
| Biofrontera INC. | $2.96 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Still listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.